Polpharma Simplifies Structure By Absorbing Subsidiaries

As Company Works To Achieve Operational Efficiency

Poland’s Polpharma SA has absorbed subsidiaries Polpharma BH and Medana Pharma as part of the group’s efforts to simplify management structures and processes and increase operational efficiency.

structuring
Polpharma BH and Medana Pharma merge into parent company Polpharma SA • Source: Alamy

Polpharma subsidiaries Polpharma BH and Medana Pharma have been merged into parent company Polpharma SA, the company has announced, as part of efforts to fulfil one of the Polpharma group’s transformation objectives “to simplify management structures and processes in order to increase operational efficiency.”

“We emphasize that, as a result of the business combination, Polpharma SA, effective from 1 April 2021, assumed all the...

Welcome to Generics Bulletin

Create an account to read this article

More from Deals

Sun Strikes Further US Price-Fixing Settlement For $200m

 
• By 

The latest development in the long-running US generic price-fixing saga has seen Sun Pharma agree a $200m settlement in connection with an end purchaser action in Pennsylvania.

Irish Ruling Gives Go-Ahead For Endo-Mallinckrodt Merger

 
• By 

A ruling from Ireland’s High Court has cleared the way for Endo and Mallinckrodt to consummate their merger in early August.

Adalvo Changes Hands As EQT Takes Control

 
• By 

Private equity firm EQT is taking control of Alvo group B2B business Adalvo, after striking a deal to acquire a majority stake from Aztiq, the investment vehicle of founder Róbert Wessman.

Samsung Bioepis Finds New US Partner For Ophthalmic Biosimilars

 
• By 

Samsung Bioepis has announced a fresh ophthalmic biosimilars partnership with Harrow, as the end approaches for a longstanding US commercialization alliance with Biogen on the Korean firm's Lucentis (ranibizumab) and Eylea (aflibercept) rivals Byooviz and Opuviz.

More from Business

Adalvo Changes Hands As EQT Takes Control

 
• By 

Private equity firm EQT is taking control of Alvo group B2B business Adalvo, after striking a deal to acquire a majority stake from Aztiq, the investment vehicle of founder Róbert Wessman.

Amphastar Unveils Plans To Quadruple US Manufacturing

 
• By 

Amphastar has announced plans to quadruple its domestic production capacity over the next three to five years. The move plays into a growing trend towards US manufacturing localization, against the backdrop of potential pharmaceutical tariffs being mooted by the Trump administration.

Samsung Bioepis Finds New US Partner For Ophthalmic Biosimilars

 
• By 

Samsung Bioepis has announced a fresh ophthalmic biosimilars partnership with Harrow, as the end approaches for a longstanding US commercialization alliance with Biogen on the Korean firm's Lucentis (ranibizumab) and Eylea (aflibercept) rivals Byooviz and Opuviz.